10-Q: Assembly Bio Faces Going Concern Doubt Amid Pipeline Progress

Assembly Biosciences reported continued losses and substantial doubt about its ability to continue as a going concern, despite advancing multiple clinical-stage antiviral programs and increasing collaboration revenue.

Summary

• Reported a net loss of $10.2 million for the three months ended June 30, 2025, and $19.0 million for the six months ended June 30, 2025.
• Cash, cash equivalents, and marketable securities totaled $75.0 million as of June 30, 2025, a decrease from $111.2 million at December 31, 2024.
• Management believes existing capital is not sufficient to fund operations beyond mid-2026, leading to substantial doubt about the company's ability to continue as a going concern.
• Collaboration revenue from Gilead Sciences, Inc. increased by 13% to $9.6 million for the three months ended June 30, 2025, and by 33% to $19.0 million for the six months ended June 30, 2025.
• Advanced multiple clinical programs, including two helicase-primase inhibitors (ABI-5366, ABI-1179) for recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor (ABI-6250), and a next-generation capsid assembly modulator (ABI-4334) for chronic hepatitis B virus (HBV) infection.
• Nominated ABI-7423 as a development candidate in the broad-spectrum non-nucleoside polymerase inhibitor (NNPI) program targeting transplant-associated herpesviruses, currently in regulatory filing-enabling preclinical studies.

Sentiment

Score: 4

Explanation: While the company reported positive clinical progress across its pipeline and increased collaboration revenue, the explicit disclosure of 'substantial doubt about its ability to continue as a going concern' and a limited cash runway into mid-2026 presents a significant financial overhang. The reliance on future financings and Gilead payments introduces considerable uncertainty, despite the promising scientific advancements.

Positives

• Collaboration revenue from Gilead Sciences, Inc. increased by 13% to $9.6 million for Q2 2025 and by 33% to $19.0 million for the six months ended June 30, 2025.
• Positive interim Phase 1a data for ABI-5366 and ABI-1179 support once-weekly/once-monthly oral dosing for recurrent genital herpes, with favorable safety profiles observed.
• ABI-6250 demonstrated target engagement and a half-life supporting once-daily oral dosing in its Phase 1a study.
• ABI-4334 Phase 1b topline results showed potent antiviral activity with significant HBV DNA declines (2.9 log10 IU/mL at 150mg, 3.2 log10 IU/mL at 400mg) and a favorable safety profile.
• Nominated ABI-7423 as a development candidate for transplant-associated herpesviruses, advancing the pipeline.

Negatives

• Incurred a net loss of $10.2 million for the three months and $19.0 million for the six months ended June 30, 2025.
• Cash, cash equivalents, and marketable securities decreased to $75.0 million as of June 30, 2025, from $111.2 million at December 31, 2024.
• Substantial doubt about the ability to continue as a going concern, with current capital expected to fund operations only into mid-2026.
• Net cash used in operating activities increased to $40.2 million for the six months ended June 30, 2025, from $35.5 million for the same period in 2024, indicating increased cash burn.
• Interest and other income, net, decreased by 39% for Q2 2025 and 35% for the six months ended June 30, 2025, primarily due to a smaller portfolio balance and lower interest rates.
• One Grade 2 alanine transaminase (ALT) elevation was observed in ABI-6250's highest single-dose cohort, with off-target engagement indicated by elevated coproporphyrin I (CP-1) levels, requiring additional studies.

Risks

• Substantial doubt exists about the ability to continue as a going concern due to recurring operating losses, negative cash flows, and uncertainty in obtaining additional financing.
• Inability to raise sufficient additional financing on reasonable terms could force staff reductions, delays or discontinuation of product development, or cessation of operations.
• Dependence on the future success of product candidates, with no approved products and no certainty of obtaining regulatory approval or successful commercialization.
• Reliance on the Gilead collaboration carries risks, including potential conflicts, Gilead not exercising opt-in rights, or Gilead developing competing products.
• Nonclinical and clinical studies are expensive, time-consuming, and may fail to demonstrate the necessary safety and efficacy for product approval.
• Reliance on Contract Research Organizations (CROs) for studies reduces control and exposes the company to risks of non-performance or compromised data quality.
• Top-line, preliminary, or interim data may not accurately reflect final study results, potentially harming or delaying product approval.
• Reliance on third parties for manufacturing increases risks of insufficient quantities, delays, or quality issues.
• Loss of key management personnel could materially adversely affect the business.
• Competition from other pharmaceutical and biotechnology companies may render product candidates obsolete or non-competitive.
• Negative clinical data from competitors with similar mechanisms of action could adversely affect public perception and regulatory approval of the company's product candidates.
• Limitations on the ability to use net operating loss and credit carryforwards due to potential ownership changes.
• Extensive and costly government regulation, with failure to comply potentially leading to sanctions, delays, or withdrawal of approvals.
• Exposure to product liability claims and potential inability to obtain sufficient insurance.
• Exposure to liability claims associated with the use of hazardous materials and chemicals.
• Risk of misconduct or improper activities by employees, contractors, or collaborators, which could result in significant liability and reputational harm.
• Inability to protect intellectual property rights could allow competitors to leverage the company's research and development efforts.
• Substantial costs may be incurred as a result of litigation or other proceedings relating to patents and other intellectual property rights.
• Risk of infringing the intellectual property rights of others, which may prevent or delay product development efforts or increase commercialization costs.
• High cost and continuous review and compliance are required for maintaining global patent protection, which may not be effectively maintained across all major markets.
• Intellectual property rights may not address all potential threats to any competitive advantage.
• The price of common stock has been and may continue to fluctuate significantly, leading to potential loss of investment.
• Bylaw provisions regarding forum selection for stockholder actions could limit stockholders' ability to bring claims in a judicial forum they find favorable.

Future Outlook

The company expects to continue incurring substantial losses as it develops product candidates and seeks regulatory approval. Current cash, cash equivalents, and marketable securities are projected to fund operations into the middle of 2026. Management plans to mitigate going concern doubt by seeking additional public or private equity financings and potential payments from the Gilead collaboration. Future capital requirements depend on clinical study progress, manufacturing, regulatory review, and intellectual property costs. The company anticipates increased operating expenses in the coming years.

Management Comments

• Based on our current operating plan, our existing cash, cash equivalents and marketable securities will be able to fund our operating requirements into the middle of 2026.
• Our plans to mitigate the conditions that raise substantial doubt about our ability to continue as a going concern include seeking additional funding through public or private equity financings and potential payments from Gilead under the Gilead Collaboration Agreement.
• We expect our future operating expenses to increase over the coming years as we continue to advance our candidates.

Industry Context

Assembly Biosciences operates in the highly competitive biotechnology sector, specifically targeting serious viral diseases like herpes, hepatitis B, and hepatitis Delta. The industry is characterized by high R&D costs, lengthy clinical development timelines, and significant regulatory hurdles. The company's focus on novel mechanisms of action (HPIs, CAMs, NNPIs, HDV entry inhibitors) positions it in a segment seeking to address limitations of current standard-of-care treatments, which often have low cure rates, high pill burdens, or limited efficacy. The collaboration with Gilead Sciences, a major pharmaceutical player, is a critical strategic move, providing funding and validation in a capital-intensive industry.

Comparison to Industry Standards

• The company's HPIs (ABI-5366, ABI-1179) are being developed to address limitations of current nucleoside analog therapies for genital herpes, which are only partially effective and carry a high pill burden (1-3 times daily). The goal of once-weekly or once-monthly oral dosing for HPIs represents a significant improvement over existing treatments like acyclovir, valacyclovir, and famciclovir, which have been approved for over 25 years without new mechanisms of action.
• ABI-6250, an HDV entry inhibitor, uses the same clinically-validated mechanism of action as bulevirtide, the only HDV therapy approved in Europe. However, bulevirtide requires daily injections, whereas ABI-6250 is an oral small molecule, which would be a significant innovation for patient convenience and treatment uptake, especially given the lack of approved HDV treatments in the U.S.
• ABI-4334, a next-generation CAM for HBV, aims to improve upon current nucleos(t)ide analog reverse transcriptase inhibitors (NrtIs) like entecavir and tenofovir, which are lifelong treatments with very low cure rates and do not directly target cccDNA. ABI-4334's dual mechanism of action (disrupting viral replication and preventing cccDNA establishment) positions it as a potentially more effective therapy compared to first-generation CAMs that primarily target viral replication.
• The company's financial position, with cash runway into mid-2026 and an accumulated deficit of $844.9 million, is typical for a clinical-stage biotechnology company that has not yet commercialized products. However, the explicit 'going concern' disclosure highlights a more immediate liquidity challenge compared to some peers with longer cash runways or more diversified funding sources.

Legal Proceedings

• Not a party to any material legal proceedings.

Related Party Transactions

• Collaboration Agreement with Gilead Sciences, Inc., under which Gilead exclusively licensed its HPI and NNPI programs to the company, and has opt-in rights to other pipeline programs.
• Gilead made an upfront cash payment of $84.8 million in October 2023.
• Gilead purchased additional shares of common stock for $20.1 million in December 2024, with a $5.2 million premium allocated to the collaboration.
• Received a non-refundable payment of $10.0 million from Gilead in December 2024 to support an accelerated development plan for ABI-6250.
• Gilead has the right to designate two directors to the company's board and owns approximately 29.9% of the company's outstanding common stock, with a right to acquire up to 35%.
• In July 2025, the company entered into a letter agreement with Gilead for reimbursement of up to $1.5 million for certain nonclinical study activities.

Stakeholder Impact

• Shareholders: Potential for significant dilution if additional equity financing is pursued; risk of substantial loss of investment due to going concern doubt; stock price volatility.
• Employees: Potential for staff reductions if additional funding is not secured.
• Customers (future): Potential for new, improved antiviral treatments for herpes, HBV, and HDV if product candidates are successfully developed and approved.
• Creditors: Increased risk due to the going concern doubt and reliance on future financing.
• Gilead Sciences, Inc.: Continued collaboration and potential for future opt-ins and milestone payments, but also risks if programs fail or options are not exercised.

Next Steps

• Explore both once-weekly and once-monthly oral dosing regimens for ABI-5366 in the Phase 1b portion of the study.
• Report interim data from the Phase 1b portion of the ABI-5366 study no later than fall 2025.
• Report interim data from the Phase 1b portion of the ABI-1179 study no later than fall 2025.
• Conduct additional studies to explore potential factors associated with ALT elevations observed in ABI-6250's Phase 1a study.
• Continue preparations for Phase 2 clinical studies for ABI-6250.
• Complete ongoing chronic toxicology studies for ABI-6250.
• Present final data from the ABI-4334 Phase 1b study at a future scientific conference.
• Continue regulatory filing-enabling preclinical studies for ABI-7423.
• Seek additional funding through public or private equity financings and potential payments from Gilead to mitigate going concern doubt.

Key Dates

Recommendation

Despite promising clinical progress in its pipeline and increased collaboration revenue from Gilead, the explicit disclosure of 'substantial doubt about its ability to continue as a going concern' and a limited cash runway into mid-2026 presents an immediate and severe financial risk. The company's reliance on uncertain future financings and Gilead's optional payments for continued operations creates significant downside risk for investors. While the scientific advancements are notable, the fundamental liquidity issue and the potential for substantial dilution or cessation of operations outweigh the positive clinical updates, making the stock a high-risk 'sell' for a seasoned investor.

Keywords

Biotechnology, Antiviral, Drug Development, Clinical Trials, Herpes, Hepatitis B, Hepatitis Delta, Going Concern, Gilead Collaboration, SEC Filing, 10-Q, Pharmaceutical, ASMB, Infectious Diseases, HPI, CAM, NNPI